GSTCGlobeStar Therapeutics Corporation

About GlobeStar Therapeutics Corporation (GSTC)

GlobeStar Therapeutics Corporation (GSTC) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the Pink tier.

GlobeStar Therapeutics Corporation ("GlobeStar"), headquartered in Richland, Washington, was incorporated in 2016 and owns breakthrough addition of treatment for Multiple Sclerosis and other neurodegenerative diseases as well other pharmaceuticals and nutraceutical. GlobeStar is a clinical stage pharmaceutical company testing a worldwide patented formulation of 3 drugs previously approved by the FDA. Pre-clinical trials in Italy showed the drug combination was effective in the reduction of MS co-morbidities. GlobeStar is initiating discussions with the FDA on clinical trial design in the U.S. in preparation for FDA submission and approval.

Products and services

GlobeStar is a clinical stage pharmaceutical company testing a worldwide patented formulation of 3 drugs previously approved by the FDA.

GSTC key facts

Ticker symbol

GSTC

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

US

Employees

2

Estimated market cap

$310.3K (as of Apr 15, 2025)

Shares outstanding

1,241,105,695

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

9/30

Latest filing

8K Report (Aug 8, 2024)

GlobeStar Therapeutics Corporation leadership

• James Carl Katzaroff — President, CEO
• Robert Chicoski — CFO, CPA, Treasurer
• Leonard Wisneski — Advisory Director
• Darryl Morris — Advisor

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with G